Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study
Table 2
Introduction of olaparib, maintenance therapy, and efficacy outcomes (n = 69).
n (%)
Time from surgery (months), median (IQR)
36 (26–63)
Chemotherapy lines before, median (IQR)
2 (2-3)
Chemotherapy lines before
2
38 (55)
3
19 (28)
4
6 (9)
5
4 (6)
≥6
2 (3)
Chemotherapy protocol before
Gemcitabine/carboplatin
10 (16)
Paclitaxel/carboplatin
45 (74)
Mono carboplatin
4 (7)
Other platin-based chemotherapy
2 (3)
Response to the chemotherapy before
Complete response
25 (36)
Partial response
44 (64)
ECOG performance status before
0
55 (80)
1
14 (20)
Formulation
Tablet
35 (51)
Capsule
34 (49)
Cycles, median (IQR)
11 (6–18)
Duration (months)
11 (7–18)
Outcomes (n = 44)
Complete response
0 (0)
Partial response
5 (11)
Stable disease
17 (39)
Progressive disease
22 (50)
Objective response rate
5 (11)
Disease control rate
22 (50)
Data are presented as number (percentage) of patients if not stated otherwise. IQR = interquartile range. Data were missing for chemotherapy protocol before introduction of olaparib for 8 (12%) patients. Efficacy outcomes were presented only for patients who had partial response to the previous chemotherapy.
